公开(公告)号：US12220462B1

公开(公告)日：2025-02-11

申请号：US17826633

申请日：2022-05-27

Applicant: ABIONYX PHARMA SA

Inventor： Jean-Louis Dasseux

IPC: A61K47/69 ,  A61K47/54 ,  A61K47/64 ,  A61P37/00

Abstract: Lipid binding protein based complexes for carrying cyclic dinucleotides (CDNs) and uses thereof, pharmaceutical compositions comprising the complexes, and methods of making the complexes.

公开(公告)号：US20250032502A1

公开(公告)日：2025-01-30

申请号：US18763757

申请日：2024-07-03

Applicant: CELGENE CORPORATION

Inventor： Peter H. SCHAFER ,  Shaojun TANG

IPC: A61K31/5377 ,  A61P37/00 ,  C12Q1/6883

Abstract: A method of determining a dose of a treatment compound for treating a subject having systemic lupus erythematosus (SLE), comprising obtaining a sample from the subject and measuring the gene expression level of IKZF3 and/or the gene expression levels of IFI27, IFI44, IFI44L, and RSAD2 in the sample.

公开(公告)号：US20250000895A1

公开(公告)日：2025-01-02

申请号：US18696397

申请日：2022-09-29

Applicant: BASF SE ,  CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL

Inventor： Günter Scherr ,  Ulrich Mrowietz

IPC: A61K31/795 ,  A01N47/34 ,  A01P1/00 ,  A61K45/06 ,  A61P31/14 ,  A61P31/18 ,  A61P31/22 ,  A61P35/00 ,  A61P37/00

Abstract: The present invention relates to a condensation product, obtained or obtainable by reaction of phenol, formaldehyde, sulfuric acid and urea, for use in a method for the treatment or prevention of a condition associated with one or more protease(s) in a subject, a pharmaceutical composition comprising such a condensation product and for such a use, a pharmaceutical set comprising such a composition and for such a use, such pharmaceutical composition and such a pharmaceutical set and the non-therapeutic use of such a condensation product, such a pharmaceutical composition or such a pharmaceutical set as a disinfectant.

公开(公告)号：US20240390425A1

公开(公告)日：2024-11-28

申请号：US18670234

申请日：2024-05-21

Applicant: HACKENSACK UNIVERSITY MEDICAL CENTER

Inventor： Jason Mathew Butler ,  Michael Gustave Poulos

IPC: A61K35/28 ,  A61P35/02 ,  A61P37/00 ,  C12N5/077 ,  C12N5/0775 ,  C12N5/0789

Abstract: The invention relates to rejuvenated hematopoietic stem cells and methods of use.

公开(公告)号：US20240384306A1

公开(公告)日：2024-11-21

申请号：US18679513

申请日：2024-05-31

Applicant: EmendoBio Inc.

Inventor： David BARAM ,  Lior IZHAR ,  Asael HERMAN ,  Rafi EMMANUEL ,  Michal GOLAN MASHIACH ,  Joseph GEORGESON

IPC: C12N15/90 ,  A61K48/00 ,  A61P37/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113

Abstract: RNA molecules comprising a guide sequence portion having 17-25 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-6601 and compostions, methods, and uses thereof.

公开(公告)号：US12129263B2

公开(公告)日：2024-10-29

申请号：US17511193

申请日：2021-10-26

Applicant: Denali Therapeutics Inc.

Inventor： Javier de Vicente Fidalgo ,  Anthony A. Estrada ,  Jianwen A. Feng ,  Brian Fox ,  Cinzia Maria Francini ,  Christopher R. H. Hale ,  Cheng Hu ,  Colin Philip Leslie ,  Maksim Osipov ,  Elena Serra ,  Zachary K. Sweeney ,  Arun Thottumkara

IPC: C07D498/04 ,  A61K31/553 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P25/00 ,  A61P27/02 ,  A61P37/00 ,  A61P43/00 ,  C07D223/16 ,  C07D267/04 ,  C07D267/14 ,  C07D413/14 ,  C07D498/10 ,  C07D519/00

CPC classification number: C07D498/04 ,  C07D223/16 ,  C07D267/04 ,  C07D267/14 ,  C07D413/14 ,  C07D519/00

Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.

公开(公告)号：US20240327486A1

公开(公告)日：2024-10-03

申请号：US18627761

申请日：2024-04-05

Applicant: Amgen Inc.

Inventor： Eric Alan BUTZ ,  Christy Ann THOMSON ,  Marc Alain GAVIN ,  Ian Nevin FOLTZ ,  Dong XIA ,  Dina N. ALCORN ,  Randal Robert KETCHEM ,  Ai Ching LIM ,  Kathy MANCHULENKO ,  Laura SEKIROV ,  Kelly Ann BERRY ,  Cyr Clovis Chua DE IMUS ,  Neeraj Jagdish AGRAWAL ,  Gunasekaran KANNAN ,  Li LI

IPC: C07K14/55 ,  A61K38/20 ,  A61P37/00 ,  C07K16/24

CPC classification number: C07K14/55 ,  A61K38/2013 ,  A61P37/00 ,  C07K16/246 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30

Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

公开(公告)号：US12091457B2

公开(公告)日：2024-09-17

申请号：US17052591

申请日：2019-05-14

Applicant: Kumho HT, Inc.

Inventor： Soseul Kim ,  Jeong Won Hong ,  Gil Yong Ji ,  Sangsoon Yoon ,  Hyung-Geun Song

IPC: A61P37/00 ,  A61P35/00 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  A61K2039/505

Abstract: The present invention relates to an antibody or an antigen-binding fragment thereof specifically binding to CD66c which is expressed in myeloid-derived suppressor cell (MDSC) and a use thereof, and specifically to an antibody or an antigen-binding fragment thereof specifically binding to CD66c, a pharmaceutical composition or a diagnosing composition including the same. The anti-CD66c antibody of the present invention can be used usefully for the treatment of various diseases by targeting MDSC which can induce the immunosuppression.

公开(公告)号：US12091441B2

公开(公告)日：2024-09-17

申请号：US17320174

申请日：2021-05-13

Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Inventor： Kenan Christopher Garcia ,  Sonia S. Majri ,  Caleb R. Glassman ,  Leon Lih-Ren Su

IPC: A61K38/20 ,  A61P37/00 ,  C07K14/55 ,  C07K16/24 ,  C12N15/63 ,  A61K9/00 ,  A61K38/00

CPC classification number: C07K14/55 ,  A61P37/00 ,  C07K16/244 ,  C12N15/63 ,  A61K9/0024 ,  A61K38/00 ,  C07K2317/74 ,  C07K2317/92 ,  C07K2319/30 ,  C07K2319/31

Abstract: Provided herein, inter alia, are human interleukin-2 (IL-2) muteins or variants thereof. In particular, provided herein are IL-2 muteins that have a decreased binding capacity for IL-2Rγ. Such IL-2 muteins are useful, for example, as IL-2 partial agonist in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of autoimmune diseases or conditions). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.

公开(公告)号：US20240287179A1

公开(公告)日：2024-08-29

申请号：US18594717

申请日：2024-03-04

Applicant: UNIVERSITY OF CONNECTICUT

Inventor： Laijun LAI

IPC: C07K16/28 ,  A61K38/00 ,  A61K39/00 ,  A61P35/00 ,  A61P37/00 ,  C07K14/705

CPC classification number: C07K16/2803 ,  A61P35/00 ,  A61P37/00 ,  C07K14/70503 ,  A61K38/00 ,  A61K2039/507

Abstract: Disclosed herein are methods for treating cancer by administering to a subject having cancer antibodies against one or more of CD300c, BTN5 (Erythroid membrane-associated protein), TAPBPL (antigen processing (TAP) binding protein like protein), Skint8 (selection and upkeep of intraepithelial T cells 8 protein), and CD300f. Also disclosed herein are methods for treating autoimmune diseases by administering to a subject having an autoimmune disease an IgV domain, or a nucleic acid encoding an IgV domain, from one or more of CD300c, BTN5, TAPBPL, Skint8, and CD300f. Also disclosed herein are antibodies against CD300c and TAPBPL, and fusion proteins that can be used in the methods for treating autoimmune disease.